조현병 스펙트럼 장애의 1년 유지 치료에서 클로자핀과 병용 치료제의 처방 양상 분석
Prescription Pattern of 1 Year Clozapine Maintenance and Augmentation Agents in Schizophrenia Spectrum Disorders
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
ObjectivesZZClozapine is the most effective atypical antipsychotic agent for the treatment-resistant schizophrenia (TRS), however, only 40%–70% of TRS patients respond to clozapine. Moreover, TRS encompasses various symptom dimensions. Therefore, augmentation with other medications for clozapine is frequently applied. However, the prescription pattern of clozapine and combined medications in Korea is yet to be examined. This study aims to investigate the maintenance treatment pattern of clozapine and augmentation agents in one Korean tertiary hospital. MethodsZZThe patients with schizophrenia spectrum disorders under clozapine maintenance, defined as one-year clozapine continuation, were subjected for analysis. Medication data at one-year time-point after clozapine initiation was extracted and analyzed. ResultsZZAmong total 2897 patients having clozapine prescription experience from January 2000 to December 2018, 1011 patients were on clozapine maintenance. The mean age of clozapine initiation was 30.2 ± 11.3 years, and the maintenance dose of clozapine was 217.8 ± 124.3 mg/day. Combination rate of antipsychotics, mood stabilizers, and antidepressants were 43.5%, 25.3%, 38.6%, respectively. Most frequently prescribed drugs in each category were aripiprazole, valproate, and sertraline. Olanzapine equivalent dose of combined antipsychotics was 10.4 ± 7.7 mg/day. Male patients were prescribed higher dose of combined antipsychotics and higher rate of antidepressants. Female patients had later onset of clozapine prescription. Patients with two or more combined antipsychotics were prescribed higher dose of clozapine and higher rate of antidepressants compared to patients with one combined antipsychotic. ConclusionsZZTaken together, among the patients taking clozapine, a substantial rate of patients were under polypharmacy. The present findings based on the real-world prescription pattern could provide the valuable clinical information on the treatment of TRSrelated conditions.
Abstract
ObjectivesZZClozapine is the most effective atypical antipsychotic agent for the treatment-resistant schizophrenia (TRS), however, only 40%–70% of TRS patients respond to clozapine. Moreover, TRS encompasses various symptom dimensions. Therefore, augmentation with other medications for clozapine is frequently applied. However, the prescription pattern of clozapine and combined medications in Korea is yet to be examined. This study aims to investigate the maintenance treatment pattern of clozapine and augmentation agents in one Korean tertiary hospital. MethodsZZThe patients with schizophrenia spectrum disorders under clozapine maintenance, defined as one-year clozapine continuation, were subjected for analysis. Medication data at one-year time-point after clozapine initiation was extracted and analyzed. ResultsZZAmong total 2897 patients having clozapine prescription experience from January 2000 to December 2018, 1011 patients were on clozapine maintenance. The mean age of clozapine initiation was 30.2 ± 11.3 years, and the maintenance dose of clozapine was 217.8 ± 124.3 mg/day. Combination rate of antipsychotics, mood stabilizers, and antidepressants were 43.5%, 25.3%, 38.6%, respectively. Most frequently prescribed drugs in each category were aripiprazole, valproate, and sertraline. Olanzapine equivalent dose of combined antipsychotics was 10.4 ± 7.7 mg/day. Male patients were prescribed higher dose of combined antipsychotics and higher rate of antidepressants. Female patients had later onset of clozapine prescription. Patients with two or more combined antipsychotics were prescribed higher dose of clozapine and higher rate of antidepressants compared to patients with one combined antipsychotic. ConclusionsZZTaken together, among the patients taking clozapine, a substantial rate of patients were under polypharmacy. The present findings based on the real-world prescription pattern could provide the valuable clinical information on the treatment of TRSrelated conditions.
참고문헌 (40)
- Crilly J, "The history of clozapine and its emergence in the US market : a review and analysis", Hist Psychiatry, 18, pp.39~60 (2007)
- 김세현, "치료저항성 조현병에서 클로자핀 치료의 현황", 대한조현병학회지, 24(1), pp.1~7 (2021), 대한조현병학회[DOI]
- Siskind D, "Clozapine v. first-and second-generation antipsychotics in treatment-refractory schizophrenia : systematic review and meta-analysis", Br J Psychiatry, 209, pp.385~392 (2016)
- Howes OD, "Treatment-resistant schizophrenia : Treatment Response and Resistance in Psychosis(TRRIP)working group consensus guidelines on diagnosis and terminology", Am J Psychiatry, 174, pp.216~229 (2017)
- Jung Suk Lee, "Korean Medication Algorithm for Schizophrenia 2019, Second Revision: Treatment of Psychotic Symptoms", Clinical Psychopharmacology and Neuroscience, 18(3), pp.386~394 (2020), 대한정신약물학회[DOI]
- Kreyenbuhl J, "The Schizophrenia Patient Outcomes Research Team(PORT) : updated treatment recommendations 2009", Schizophr Bull, 36, pp.94~103 (2010)
- Hasan A, "World Federation of Societies of Biological Psychiatry(WFSBP)Guidelines for Biological Treatment of Schizophrenia, part 1 : update 2012 on the acute treatment of schizophrenia and the management of treatment resistance", World J Biol Psychiatry, 13, pp.318~378 (2012)
- Remington G, "Guidelines for the pharmacotherapy of schizophrenia in adults", Can J Psychiatry, 62, pp.604~616 (2017)
- Keepers GA, "The American Psychiatric Association Practice Guideline for the Treatment of Patients with Schizophrenia", Am J Psychiatry, 177, pp.868~872 (2020)
- Samanaite R, "Biological predictors of clozapine response : a systematic review", Front Psychiatry, 9, pp.327~ (2018)
- 이건석, "치료저항성 조현병: 정의와 임상양상", 대한조현병학회지, 23(2), pp.45~50 (2020), 대한조현병학회[DOI]
- Taylor DM, "Augmentation of clozapine with a second antipsychotic-a meta-analysis", Acta Psychiatr Scand, 125, pp.15~24 (2012)
- Siskind DJ, "Augmentation strategies for clozapine refractory schizophrenia : a systematic review and meta-analysis", Aust N Z J Psychiatry, 52, pp.751~767 (2018)
- Wagner E, "Clozapine augmentation strategies-a systematic meta-review of available evidence. Treatment options for clozapine resistance", J Psychopharmacol, 33, pp.423~435 (2019)
- Roerig JL, "Clozapine augmentation strategies", Ment Health Clin, 9, pp.336~348 (2019)
- Bartoli F, "Adjunctive second-generation antipsychotics for specific symptom domains of schizophrenia resistant to clozapine : a meta-analysis", J Psychiatr Res, 108, pp.24~33 (2019)
- Tiihonen J, "Association of antipsychotic polypharmacy vs monotherapy with psychiatric rehospitalization among adults with schizophrenia", JAMA Psychiatry, 76, pp.499~507 (2019)
- Gallego JA, "Prevalence and correlates of antipsychotic polypharmacy : a systematic review and meta-regression of global and regional trends from the 1970s to 2009", Schizophr Res, 138, pp.18~28 (2012)
- Latimer E, "Underprescribing of clozapine and unexplained variation in use across hospitals and regions in the Canadian province of Québec", Clin Schizophr Relat Psychoses, 7, pp.33~41 (2013)
- Xiang YT, "Use of clozapine in older Asian patients with schizophrenia between 2001 and 2009", PLoS One, 8, pp.e66154~ (2013)
- Bachmann CJ, "International trends in clozapine use : a study in 17 countries", Acta Psychiatr Scand, 136, pp.37~51 (2017)
- Green AI, "Detection and management of comorbidity in patients with schizophrenia", Psychiatr Clin North Am, 26, pp.115~139 (2003)
- 윤제연, "‘2019 한국형 조현병 약물치료 지침서’에 따른 조현병에서 동반증상 및 부작용의 치료", 대한조현병학회지, 22(2), pp.21~33 (2019), 대한조현병학회[DOI]
- Li XB, "Clozapine for treatment-resistant bipolar disorder : a systematic review", Bipolar Disord, 17, pp.235~247 (2015)
- Gardner DM, "International consensus study of antipsychotic dosing", Am J Psychiatry, 167, pp.686~693 (2010)
- Inada T, "Psychotropic dose equivalence in Japan", Psychiatry Clin Neurosci, 69, pp.440~447 (2015)
- Wheeler AJ, "Treatment pathway and patterns of clozapine prescribing for schizophrenia in New Zealand", Ann Pharmacother, 42, pp.852~860 (2008)
- Harrison J, "Patterns of clozapine prescribing in a mental health service in New Zealand", Pharm World Sci, 32, pp.503~511 (2010)
- Tungaraza TE, "Prescribing pattern of clozapine and other antipsychotics for patients with first-episode psychosis : a cross-sectional survey of early intervention teams", Ther Adv Psychopharmacol, 7, pp.103~111 (2017)
- Yi W, "Clozapine use in patients with early-stage schizophrenia in a Chinese psychiatric hospital", Neuropsychiatr Dis Treat, 16, pp.2827~2836 (2020)
- Verdoux H, "Clozapine use pattern in persons with and without treatment for Parkinson’s disease in real-world conditions : a naturalistic study in a community-based sample", Acta Psychiatr Scand, 130, pp.487~497 (2014)
- Lally J, "Two distinct patterns of treatment resistance : clinical predictors of treatment resistance in first-episode schizophrenia spectrum psychoses", Psychol Med, 46, pp.3231~3240 (2016)
- Bozzatello P, "Predictive factors of treatment resistance in first episode of psychosis : a systematic review", Front Psychiatry, 10, pp.67~ (2019)
- Kinon BJ, "The group of treatment resistant schizophrenias. Heterogeneity in treatment resistant schizophrenia(TRS)", Front Psychiatry, 9, pp.757~ (2019)
- Singh A, "Prevalence and clinical correlations of obsessive-compulsive symptoms in schizophrenia", Asian J Psychiatr, 39, pp.48~52 (2019)
- Zheng W, "Clozapine augmentation with antiepileptic drugs for treatment-resistant schizophrenia : a meta-analysis of randomized controlled trials", J Clin Psychiatry, 78, pp.e498~e505 (2017)[DOI]
- Wong J, "Clozapine-induced seizures : recognition and treatment", Can J Psychiatry, 52, pp.457~463 (2007)
- Poyurovsky M, "Obsessive-compulsive disorder in schizophrenia : clinical characteristics and treatment", CNS Drugs, 18, pp.989~1010 (2004)
- Sa AR, "Obsessive-compulsive symptoms and disorder in patients with schizophrenia treated with clozapine or haloperidol", Compr Psychiatry, 50, pp.437~442 (2009)
- Spina E, "Plasma concentrations of clozapine and its major metabolites during combined treatment with paroxetine or sertraline", Pharmacopsychiatry, 33, pp.213~217 (2000)